RESULTS	Urinary deoxypyridinoline normalized in 87 % of patients on risedronate and 57 % of patients receiving etidronate ( P < 0.01 ) ; serum bone-specific alkaline phosphatase normalized in 73 % of patients on risedronate and 18 % of patients on etidronate ( P < 0.001 ) .\